Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Follow us on Google+Follow us on TwitterFind us on LinkedInFind Us on FacebookSubscribe to our RSS FeedsSubscribe to our YouTube ChannelFind us on RebelMouse

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for April 23, 2013 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version   



Kidney dialysis product maker may be liable for harmful side-effects

Fresenius knew of the dangers of its dialysis products prior to the FDA recall, but did not warn patients. The company may be liable for the harm that its products caused to patients.
 
x-small text small text medium text large text

    April 23, 2013 /24-7PressRelease/ -- According to the Centers for Disease Control and Prevention, one in 10 adults in the U.S. has some form of chronic kidney disease which reduces kidney function over a period of time. One of the ways that people treat kidney disease is through the use of a dialysis machine to perform the blood filtering operation that the kidneys usually do. Few people suspect that by treating one disease they may be putting themselves at risk for other potentially fatal conditions. However, the FDA issued a recall of Fresenius Medical Care Naturalyte and GranuFlo dialysis products after reports that people had died after using them. Fresenius knew of the dangers prior to the recall, but did not warn patients. As such, Fresenius may be liable for the harm that its products caused to patients.

FDA recall of dialysis products

On March 29, 2012 the U.S. Food and Drug Administration issued a Class I recall of Naturalyte and GranuFlo, the most serious type of recall involving products that have a reasonable certainty of causing serious health problems or death. The reason that the FDA recalled the products was due to reports that patients had developed dangerously high levels of serum bicarbonate after undergoing dialysis. High levels of serum bicarbonate can cause cardiac arrest, cardiopulmonary arrest, stroke, low blood pressure and possibly death.

Manufacturer knew of dangers

An internal memo that Fresenius issued in November 2011 revealed that the company was aware that patients were dying as a result of using their dialysis products. The memo informed doctors working in Fresenius clinics across the country that "only" 941 patients had died from cardiac complications due to elevated levels of serum bicarbonate. The memo also noted that patients using Fresenius dialysis products were six times more likely to suffer cardiac arrest than those who used competitors' dialysis products.

The company chose not to broadcast this information to doctors outside its own clinics, even though it sold its dialysis products to other health care providers, until the FDA obtained a copy of the internal memo and forced a product recall.

Speak with an attorney

When medical product manufacturers discover the products they make cause harm, they have a responsibility to inform people. Medical product manufacturers need to be held responsible for the harm that their products cause, as well. If you or a loved one has suffered injury after undergoing dialysis, speak with an experienced personal injury attorney who can help you recover just and proper compensation.

Article provided by Herrman & Herrman, P.L.L.C.
Visit us at www.herrmanandherrman.com



---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #

Read more Press Releases from FL Web Advantage:


Contact Information:
FL Web Advantage

E-Mail: Email us Here
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7PressRelease. We are unable to assist you with any information regarding this release. 24-7PressRelease disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.